|
Aurobindo Pharma Limited
(www.aurobindo.com), headquartered at Hyderabad,
India, manufactures generic pharmaceuticals and
active pharmaceutical ingredients.
The company has received
approvals for most of the targeted API and
formulation facilities from leading regulatory
agencies such as US FDA, UK MHRA, WHO, Health
Canada, MCC South Africa.
The company’s robust product portfolio is spread
over 6 major therapeutic/product areas
encompassing Antibiotics, Anti-Retrovirals, CVS,
CNS, Gastroenterologicals, and Anti-Allergics.
The formulation portfolio is
built on six technology platforms such as
immediate release generics, SR/CR generics,
orally disintegrating/mouth dissolving generics,
combination products, sterile/lyophilized
generics and liquids/dry syrups.
Aurobindo has filed over 100 DMFs
and 75 ANDAs for the USA market in addition to
filings in other countries. The pace of filings
is matched by rapid product approvals from
various markets. Till date Aurobindo has
received 37 ANDA approvals (both final and
tentative) from US FDA.
Aurobindo operates in over 100
countries and markets over 180 APIs and 250
formulations |
PRESS
ROOM
